Sparks

Tissue Regenix (LSE: TRX) announces H124 results

Tissue Regenix’s H124 results reflect sustained progress across its multiple areas of business, with revenues increasing by 16% to US$16.4m (H123: US$14.1m). This was largely driven by the robust performance of its key technology platforms, BioRinse (sales up by 12% to US$10.5m; H123: US$9.4m) and dCELL (sales up by 34% to US$4.2m; H123: US$3.1m). Gross profit also increased to 53% (H123: 49%) due to greater processing efficiencies and a favourable product mix. The company ended the period with a cash position of US$3.5m, which should see it through current business plans, including the Phase 2 capacity expansion of its San Antonio facility, expected to complete in 2025. Collectively, these results mark Tissue Regenix’s eighth consecutive period of growth and the seventh consecutive period of double-digit, half-on-half growth.

Next Sparks Commentary in this sector >

Latest

Industrials | Comment

03.07.25

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Equities

Equities by Sector

Sectors

Thematics

Latest

Decarbonising the built environment – Green materials, greener buildings

The advertising ecosystem – Triangulating perspectives

JPMorgan European Discovery Trust – The power of small

Audiovisual

Latest

Vantage: VOF – inside Vietnam’s investment boom (27 June 2025)

Cereno Scientific – executive interview

Partners Group Private Equity in 60 seconds

About Edison

About Edison

Careers

Sparks

Latest

THEON INTERNATIONAL (AMS: THEON) – additional order intake

Baltic Classifieds (LSE: BCG) continued good progress

Cereno Scientific (STO: CRNO-B) enters the FN25 Index

AAC Clyde Space (OTCQX: AAC) share issue raising SEK64.5m

Hercules (AIM: HERC) acquire Advantage NRG for up to £15.7m

Subscribe to Edison